Jeronimo C Cello

US Patent:

20090246216, Oct 1, 2009

Filed:

Mar 16, 2009

Appl. No.:

12/405068

Inventors:

Eckard Wimmer - E. Setauket NY, US
Jeronimo Cello - Port Jefferson NY, US
Aniko Paul - Setauket NY, US
Hidemi Toyoda - E. Setauket NY, US
Jiang Yin - Port Jefferson NY, US

Assignee:

The Research Foundation of State University of New York - Albany NY

International Classification:

A61K 39/13
C12N 7/01
A61P 35/00
C12N 7/06

US Classification:

4241861, 4352351, 4242051, 435238

Abstract:

A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2atumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.

US Patent:

20100209454, Aug 19, 2010

Filed:

Mar 31, 2008

Appl. No.:

12/594173

Inventors:

Eckard Wimmer - East Setauket NY, US
Steve Skiena - Setauket NY, US
Steffen Mueller - Kings Point NY, US
Bruce Futcher - Stony Brook MA, US
Dimitris Papamichail - South Miami FL, US
John Robert Coleman - Blauvelt NY, US
Jeronimo Cello - Port Jefferson NY, US

International Classification:

A61K 39/12
A61P 31/14
A61P 31/16
A61P 31/20
A61P 31/22
A61P 31/18
C12N 7/04

US Classification:

4242051, 435236

Abstract:

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

US Patent:

20120064113, Mar 15, 2012

Filed:

Oct 7, 2011

Appl. No.:

13/269213

Inventors:

Eckard Wimmer - E. Setauket NY, US
Jeronimo Cello - Port Jefferson NY, US
Aniko Paul - Setauket NY, US
Hidemi Toyoda - E. Setauket NY, US
Jiang Yin - Port Jefferson NY, US

Assignee:

The Research Foundation of State University of New York - Albany NY

International Classification:

A61K 35/76
C12N 7/01
A61P 35/00

US Classification:

4241991, 424 932, 4352351

Abstract:

A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2atumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.

US Patent:

20120269849, Oct 25, 2012

Filed:

Oct 11, 2010

Appl. No.:

13/501045

Inventors:

Eckard Wimmer - East Setauket NY, US
Steve Skiena - Setauket NY, US
Steffen Mueller - Kings Point NY, US
Bruce Futcher - Stony Brook NY, US
Dimitris Papamichail - South Miami FL, US
John Robert Coleman - Blauvelt NY, US
Jeronimo Cello - Port Jefferson NY, US

International Classification:

A61K 39/12
C12N 7/04
A61P 31/12
C12N 15/54

US Classification:

4242041, 536 232, 435236

Abstract:

The present provides attenuated influenza viruses comprising a modified viral genome containing a plurality of nucleotide substitutions. The nucleotide substitutions result in the rearrangement of preexisting codons of one or more protein encoding sequences and changes in codon pair bias. Substitutions of non-synonymous and synonymous codons may also be included. The attenuated influenza viruses enable production of improved vaccines and are used to elicit protective immune responses.

US Patent:

20220298492, Sep 22, 2022

Filed:

Oct 28, 2021

Appl. No.:

17/513032

Inventors:

- Albany NY, US
Steve Skiena - Setauket NY, US
Steffen Mueller - Kings Point NY, US
Bruce Futcher - Setauket NY, US
Dimitris Papamichail - Newtown PA, US
John Robert Coleman - Blauvelt NY, US
Jeronimo Cello - Port Jefferson NY, US

International Classification:

C12N 7/00
A61K 39/12
A61K 39/13
A61K 39/145
C07K 14/005

Abstract:

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

US Patent:

20190010469, Jan 10, 2019

Filed:

Jul 16, 2018

Appl. No.:

16/036348

Inventors:

- Albany NY, US
Steve Skiena - Setauket NY, US
Steffen Mueller - Kings Point NY, US
Bruce Futcher - Stony Brook NY, US
Dimitris Papamichail - Newtown PA, US
John Robert Coleman - Blauvelt NY, US
Jeronimo Cello - Port Jefferson NY, US

International Classification:

C12N 7/00
A61K 39/145
C07K 14/005
A61K 39/13
A61K 39/00

Abstract:

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

US Patent:

20170067030, Mar 9, 2017

Filed:

Sep 7, 2016

Appl. No.:

15/258584

Inventors:

- Albany NY, US
Steve Skiena - Setauket NY, US
Steffen Mueller - Kings Point NY, US
Bruce Futcher - Stony Brook NY, US
Dimitris Papamichail - Pennington NJ, US
John Robert Coleman - Blauvelt NY, US
Jeronimo Cello - Port Jefferson NY, US

International Classification:

C12N 7/00
A61K 39/13
A61K 39/145
C07K 14/005

Abstract:

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

US Patent:

20140356962, Dec 4, 2014

Filed:

Dec 14, 2012

Appl. No.:

14/365854

Inventors:

- Albany NY, US
Jeronimo Cello - Port Jefferson NY, US
Ying Liu - Port Jefferson NY, US

International Classification:

C12N 7/00

US Classification:

435471, 435236, 536 232

Abstract:

A novel and stable attenuated poliovirus is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region (with inactivation of the native ere element located in the coding region of 2C (mono-crePV), and replacing the nucleic acid sequence of all or part of the capsid coding region (PI) with a substitute PI coding region having reduced codon pair bias. The stably attenuated poliovirus is effective for vaccines and immunization.